Voltage-controlled magnetic skyrmions have attracted special attention because they satisfy the requirements for well-controlled high-efficiency and energy saving for future skyrmion-based neuron device applications.I...Voltage-controlled magnetic skyrmions have attracted special attention because they satisfy the requirements for well-controlled high-efficiency and energy saving for future skyrmion-based neuron device applications.In this work,we propose a compact leaky-integrate-fire(LIF)spiking neuron device by using the voltage-driven skyrmion dynamics in a multiferroic nanodisk structure.The skyrmion dynamics is controlled by well tailoring voltage-induced piezostrains,where the skyrmion radius can be effectively modulated by applying the piezostrain pulses.Like the biological neuron,the proposed skyrmionic neuron will accumulate a membrane potential as skyrmion radius is varied by inputting the continuous piezostrain spikes,and the skyrmion radius will return to the initial state in the absence of piezostrain.Therefore,this skyrmion radius-based membrane potential will reach a definite threshold value by the strain stimuli and then reset by removing the stimuli.Such the LIF neuronal functionality and the behaviors of the proposed skyrmionic neuron device are elucidated through the micromagnetic simulation studies.Our results may benefit the utilization of skyrmionic neuron for constructing the future energy-efficient and voltage-tunable spiking neural networks.展开更多
目的研究视网膜激光光凝术联合雷珠单抗对视网膜分支静脉阻塞(BRVO)继发黄斑水肿(ME)疗效及安全性影响。方法选取2013年10月-2016年10月在本院接受治疗的BRVO继发ME患者共300例(300眼),随机分为单一注射组150例(150眼),按照0.04 m L/0.4...目的研究视网膜激光光凝术联合雷珠单抗对视网膜分支静脉阻塞(BRVO)继发黄斑水肿(ME)疗效及安全性影响。方法选取2013年10月-2016年10月在本院接受治疗的BRVO继发ME患者共300例(300眼),随机分为单一注射组150例(150眼),按照0.04 m L/0.4 mg标准给予患者注射雷珠单抗,每个月注射一次,一共注射3个月;联合治疗组150例(150眼),按照上面标准每月给患者注射一次雷珠单抗,并在第一次注射一周后对患者行格栅样视网膜激光光凝术(GLP)。结果经过治疗后两组患者黄斑中心凹厚度(CMT)均有下降、最佳矫正视力(BCVA)均有上升,联合治疗组效果优于单一注射组,差异均有统计学意义(P<0.05);荧光素眼底血管造影术(FFA)检测结果显示,联合治疗组患者在治疗3个月后血管渗漏现象明显改善,优于单一注射组,差异有统计学意义(P<0.05)。结论视网膜激光光凝术联合雷珠单抗可以降低BRVO-ME患者的CMT,改善其ME,视力得到提高,且治疗效果明显优于单一注射雷珠单抗者。展开更多
基金the National Natural Science Foundation of China(Grant Nos.11902316,51902300,and 11972333)the Natural Science Foundation of Zhejiang Province,China(Grant Nos.LQ19F010005,LY21F010011,and LZ19A020001).
文摘Voltage-controlled magnetic skyrmions have attracted special attention because they satisfy the requirements for well-controlled high-efficiency and energy saving for future skyrmion-based neuron device applications.In this work,we propose a compact leaky-integrate-fire(LIF)spiking neuron device by using the voltage-driven skyrmion dynamics in a multiferroic nanodisk structure.The skyrmion dynamics is controlled by well tailoring voltage-induced piezostrains,where the skyrmion radius can be effectively modulated by applying the piezostrain pulses.Like the biological neuron,the proposed skyrmionic neuron will accumulate a membrane potential as skyrmion radius is varied by inputting the continuous piezostrain spikes,and the skyrmion radius will return to the initial state in the absence of piezostrain.Therefore,this skyrmion radius-based membrane potential will reach a definite threshold value by the strain stimuli and then reset by removing the stimuli.Such the LIF neuronal functionality and the behaviors of the proposed skyrmionic neuron device are elucidated through the micromagnetic simulation studies.Our results may benefit the utilization of skyrmionic neuron for constructing the future energy-efficient and voltage-tunable spiking neural networks.
文摘目的研究视网膜激光光凝术联合雷珠单抗对视网膜分支静脉阻塞(BRVO)继发黄斑水肿(ME)疗效及安全性影响。方法选取2013年10月-2016年10月在本院接受治疗的BRVO继发ME患者共300例(300眼),随机分为单一注射组150例(150眼),按照0.04 m L/0.4 mg标准给予患者注射雷珠单抗,每个月注射一次,一共注射3个月;联合治疗组150例(150眼),按照上面标准每月给患者注射一次雷珠单抗,并在第一次注射一周后对患者行格栅样视网膜激光光凝术(GLP)。结果经过治疗后两组患者黄斑中心凹厚度(CMT)均有下降、最佳矫正视力(BCVA)均有上升,联合治疗组效果优于单一注射组,差异均有统计学意义(P<0.05);荧光素眼底血管造影术(FFA)检测结果显示,联合治疗组患者在治疗3个月后血管渗漏现象明显改善,优于单一注射组,差异有统计学意义(P<0.05)。结论视网膜激光光凝术联合雷珠单抗可以降低BRVO-ME患者的CMT,改善其ME,视力得到提高,且治疗效果明显优于单一注射雷珠单抗者。
